Fundraising Fox
Boston · Pre-Seed–Late Stage · 51 people tracked
Also known as MPM ASSET MANAGEMENT LLC · MPM Capital
Find your way into MPM BioImpact
Sign up to see every warm intro you have to MPM BioImpact
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MPM BioImpact team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
MPM BioImpact leverages three decades of biotech venture expertise combined with impact investing principles to support companies across all drug development phases. The firm invests in both private and public biotech companies that aim to meaningfully improve patient outcomes and transform treatment of disease, while maintaining commitment to global impact investment standards.
Source: firm website, verified Oct 27, 2026.
Team · 51 people
from the firm's website & curated & public directories
Managing Partner who founded MPM Capital in 1992 and later affiliate BioImpact Capital; lead investor behind companies such as BioMarin, Pharmasset and Orna Therapeutics. Holds an M.D. from J.W. Goethe University in Frankfurt.
Chairman of MPM BioImpact with medical doctorate, involved in identifying and leading transformative therapeutic investments.
Entrepreneur Partner and founder/CEO of portfolio company Umoja Biopharma; formerly an attending physician and professor at Seattle Children's/University of Washington and CSO of Cellectis Therapeutics. Holds an M.D. from UNC School of Medicine.
Entrepreneur Partner and co-founder/CEO of Reversing Early Recurrence; a gastrointestinal oncologist and Associate Professor at Harvard Medical School directing MGH cancer programs. Holds an M.D. from Indiana University School of Medicine.
Entrepreneur Partner serving on the board of portfolio company NextPoint Therapeutics; formerly Chief Business Officer at Orna Therapeutics and SVP of Corporate Development at Bristol Myers Squibb. Holds an M.B.A. from New York University.
Entrepreneur Partner and CEO of portfolio company Crossbow Therapeutics; formerly CMO and EVP of Global Medicines Development at AstraZeneca, with prior roles at Pfizer and Merck. Holds an M.D. from the University of Connecticut.
Managing Partner at MPM BioImpact who led the firm's early public investment in argenx.
Managing Partner at MPM BioImpact with medical background, involved in early investment identification and portfolio strategy.
Managing Partner leading MPM BioImpact's public market investing as portfolio manager for BioImpact Equities and the Oncology Impact Funds; formerly a healthcare analyst at Fidelity Investments. Holds an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.
Entrepreneur Partner and Senior Clinical Advisor to Rhythm Pharmaceuticals; a biopharma executive who has held leadership roles at multiple portfolio companies and was SVP of Global Clinical Development Operations at Merck. Holds an M.D. from Albert Einstein College of Medicine.
Entrepreneur Partner and Acting CMO at portfolio company K2 Therapeutics; formerly SVP and Global Head of Clinical Development at Kite (a Gilead Company). Holds an M.D. from Heinrich Heine University and a Ph.D. from the University of Bonn.
Executive Partner managing the firm's Investment Committees; joined in 2017 and previously served as its COO and CFO, with prior CFO roles at Atlas Venture, Flare Capital Partners and Softbank Capital. Holds an M.B.A. from Boston University.
Entrepreneur Partner and CEO of portfolio company Aktis Oncology; formerly SVP and Head of Enterprise Strategy at Bristol Myers Squibb and Head of Biotech Equity Research at UBS. Holds a Ph.D. from Albert Einstein College of Medicine.
Entrepreneur Partner and CEO of portfolio company Ashibio; formerly VP and Head of Oncology at Gilead Sciences and CMO at Dicerna Pharmaceuticals. Holds an M.D. from the University of Delhi.
Partner responsible for identifying and diligencing public equity investments; spent his career in oncology drug discovery, most recently as Senior Director of Cancer Biology at Scorpion Therapeutics. Holds a Ph.D. in Genetics from MIT.
Head of APAC focused on early-stage investment and company creation in the region; previously spent 16 years at Temasek investing in healthcare companies. Holds an M.S. in biotechnology from Johns Hopkins.
Principal responsible for investment identification, diligence and company creation in the APAC region; previously spent five years at Hillhouse Capital covering global healthcare investments. Holds a Ph.D. from UCLA.
Principal focused on early-stage investments and company creation; previously spent seven years at 8VC where he co-led its bio practice. Holds a Ph.D. in Biomedical Informatics and M.S. in Statistics from Stanford.
Managing Director and serial biopharma entrepreneur; recently CEO of portfolio company NextPoint Therapeutics and formerly President/CEO of Surface Oncology, with prior senior roles at AstraZeneca and Novartis.
Managing Director who joined MPM in 1999 and chairs several portfolio company boards including Aktis Oncology and Crossbow Therapeutics; previously worked in business development at Genentech. Holds an M.B.A. from Harvard Business School.
Principal focused on private investments and new company formation, also VP of Discovery Strategy at an MPM stealth company; previously Principal at Apple Tree Partners. Holds a Ph.D. from Harvard University.
William Greene is Chief Investment Officer at Hevolution Foundation. He brings experience across biotechnology investment, operational leadership, and clinical development, including roles as CEO of two life sciences startups and board positions at venture capital firms. His background encompasses neuroscience and epidemiology research, clinical program leadership, and global venture capital investing.
Chief Compliance Officer; formerly a Senior Principal Consultant at ACA Group supporting fund compliance programs, with earlier compliance roles at AdvisorAssist and Key Bank. Holds a JD from Suffolk University Law School.
Chairs MPM BioImpact's Medical and Scientific Advisory Board; a Stanford chemistry professor and HHMI investigator who shared the 2022 Nobel Prize in Chemistry for founding bioorthogonal chemistry and has co-founded 12 biotech companies.
Head of Fund Investor Relations and Strategic Finance leading fundraising and investor engagement for MPM's private funds; formerly a Senior Director at Flagship Pioneering. Holds an M.B.A. from Boston University.
Director of Investor Relations coordinating existing and prospective investor relations; previously worked at Turbonomic and as a sales consultant raising capital for private companies. Holds an M.B.A. from Northeastern University.
Chief Financial Officer overseeing the firm's finance functions; previously CFO at Lincoln Peak Capital, HighVista Strategies and Abrams Capital. Holds an M.S./M.B.A. from Northeastern University.
Vice President of Legal; previously worked at 5AM Ventures and Moderna advising on licensing and M&A, and began her career at Kirkland & Ellis. Holds a JD from George Washington University Law School.
IP Counsel to several MPM portfolio companies; previously VP of IP at Flagship Ventures and a patent attorney at national law firms. Holds a J.D. from Suffolk University Law School and a Ph.D. from Tufts University School of Medicine.
General Counsel; spent 35 years at Sullivan & Cromwell advising on complex transactions across capital markets, finance, M&A and restructuring. Holds a J.D. from Yale Law School.
Senior Associate responsible for identifying and diligencing public equity investments; formerly an MPM fellow. Completed a Ph.D. in Computational and Systems Biology at MIT focused on AI/ML for molecular analysis.
Founder mafia
14 people who came through MPM BioImpact went on to found or lead other companies.
+ 2 more
What they invest in
from 56 of 67 portfolio companiesBiotech ×52Healthtech ×23Medical Devices ×14AI & Machine Learning ×6Digital Health ×6Deep Tech ×4Longevity ×3Consumer ×1
HQs:United States×48United Kingdom×1
Who they back
founder profiles across 12 portfolio companiesFounding team size:solo founder×52 founders×44+ founders×3
Where their founders worked beforefrom 11 founders with career history
Longwood Fund ×3Harvard Medical School ×2Maverick Therapeutics ×2Potenza Therapeutics ×2Trieza Therapeutics ×2Vesuvius Pharmaceuticals ×2
Investments · 67 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 52024 · 42023 · 22022 · 22021 · 42020 · 52019 · 52018 · 42017 · 42016 · 42015 · 252 dated
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Board seatTodd Foley· per SEC Form D
Co-investorsAndreessen HorowitzEcoR1 CapitalMRL Ventures FundPappas CapitalRA CapitalTCG Crossover+5 more
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Board seatTodd Foley· per SEC Form D
Co-investors5AM VenturesAgent CapitalMRL Ventures FundRoche Venture FundTCG CrossoverWellington Management
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(President and Chief Executive Officer)in
Co-investorsAtlas VentureHercules Capital, Inc.Vida VenturesWellington ManagementForbionRA Capital
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 Capital+6 more
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)Andrew Scharenberg(Founder)Michael Jensen(Founder)Philip Low(Founder)Ryan Crisman(Founder)
Board seatLuke Evnin· per SEC Form D
Co-investorsDCVC BioQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundAlexandria+2 more
Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease.
BiotechHealthtechLa Jolla, US
Peter Flynn, Ph.D.(Executive Officer, Director)
BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)inAshish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)
Co-investorsAvalon BioVenturesCatalys Pacific
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.
BiotechHealthtechLongevity
Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)
Co-investorsVersant VenturesDCVC BioLilly Asia VenturesDCVC (Data Collective)
Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.
BiotechHealthtechLongevityWaltham, US
Amit Choudhary(Scientific Founder)David Steinberg(Chairman & Founding CEO)inEdward Holson(Co-founder & CSO)inLizzie Ngo(Co-founder)inBrian Fenton(President & CEO)in
Co-investorsLongwood Fund8VCMRL Ventures FundOno Venture Investment, Inc.
Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.
AI & Machine LearningBiotechHealthtech
Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)inCourtney Beers(Chief Scientific Officer)
Co-investorsCanaan PartnersAbingworthGilead SciencesAstellas Venture Management LLCLightstone Ventures
Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers.
BiotechHealthtech
Anil Singhal(President and CEO)inSiddhartha Mitra(Chief Medical Officer)in
Co-investorsCanaan PartnersAstellas Venture Management LLCLightstone Ventures
Vascular Pharmaceuticals develops VPI-2960B, a therapeutic candidate in clinical development for diabetic nephropathy treatment.
BiotechDigital HealthMedical DevicesChapel Hill, US
Laura Maile(Co-Founder, Director, Research and Development)Richard Shea(Executive Officer, Director)inBonnie Layman(Executive Officer)David Clemmons(Co-Founder, Chief Scientific Officer)
BoardElizabeth Stoner(Director)inRichard Kent(Director)
BiotechNewton Centre, US
Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)
BoardScott Minick(Director)inTodd T. Foley(Director)inVincent Miles(Director)Ansbert K. Gadicke(Director)in
Board seatBard GeesamanDavid StackAnsbert Gadicke· per SEC Form D
Co-investorsHEALTHCARE ROYALTY PARTNERSSofinnova VenturesAbingworthARCH Venture Partners
Clinicalink offers a digital tool designed to improve drug adherence and measure the functional quality of weight loss.
Digital HealthHealthtechSaaSWinston-Salem, US
Douglas E. Pierce, Jr.(Executive Officer, Director, Promoter)Joe Schmidt(Executive Officer)Edward S. Seguine(Executive Officer, Director, Promoter)
BoardMatt King(Director)inBrad Geesaman(Director)
Board seatTony RosenbergTodd FoleyAnsbert Gadicke· per SEC Form D
Co-investorsFCA Venture PartnersMcKesson Ventures
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Board seatTodd Foley· per SEC Form D
Co-investorsLifelinkPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPfizer VenturesPolaris Partners+1 more
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Board seatLuke Evnin· per SEC Form D
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesFelicis VenturesRA CapitalDCVC Bio+2 more
A research-intensive biopharmaceutical company that develops medicines and vaccines.
BiotechHealthtechSouth San Francisco, US
Luke Nathaniel Walker(Executive Officer)Julie Eastland(Executive Officer, Director)in
BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)
Board seatPatrick BaeuerleLuke EvninPablo CagnoniDan Hicklin· per SEC Form D
Co-investorsK2 HealthVenturesRidgeback CapitalTaiho Ventures, LLCArix BioscienceLilly Asia VenturesNew Leaf Venture Partners+1 more
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)
Board seatDetlev Biniszkiewicz· per SEC Form D
Co-investorsCatalio Capital Management, LPSanofi VenturesCatalio Capital ManagementInvusLeaps by BayerSixty Degree Capital
Cambridge, US
Christophe Queva(Executive Officer)inTheodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)Cameron Wheeler(Director)in
Board seatMitchell FinerLuke EvninBriggs Morrison· per SEC Form D
Co-investorsAstellas Venture Management LLCCowen Healthcare InvestmentsDeerfield Management CompanyIMM InvestmentK2 HealthVenturesSphera Funds Management
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.
BiotechDigital HealthMental HealthMorristown, US
Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in
Board seatAnsbert Gadicke· per SEC Form D
Co-investorsFemHealth VenturesMitsui Global InvestmentPalo Santo VCNovo Holdings
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDavid Cordo(Executive Officer)Alon Lazarus(Director)
BoardChristoph Westphal(Director)
Board seatLuke EvninBriggs Morrison· per SEC Form D
Co-investorsDC Investment PartnersK2 HealthVenturesLongwood FundRA CapitalTaiho Ventures, LLCUPMC Enterprises
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in
Co-investorsDroia VenturesFrazier Life SciencesNovartis Venture FundRV Invest GmbHFrazier Healthcare PartnersRTW Investments L.P.+1 more
Co-investorsVersant VenturesVivo Capital
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalAvestria VenturesBrace PharmaCanaan PartnersGaingelsGV (Google Ventures)+6 more
__Twitter.png)
The company develops therapies for people with severe autoimmune diseases.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsBioGeneration VenturesHBM Healthcare InvestmentsOmnes CapitalPMVSeventure Partners+3 more
āshibio is a biotech company developing novel therapies for rare bone and connective tissue disorders, led by a team of scientists, physicians and drug developers.
BiotechHealthtechBurlingame, US
Pankaj Bhargava(Founder & Chief Executive Officer)inVictoria Smith(Chief Scientific Officer)Deborah Wenkert(Chief Medical Officer)inJoseph Sarret(Acting Chief Operating Officer)Brian Shuster(Acting Chief Business Officer)
Co-investorsAgent Capital
AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.
BiotechDeep TechHealthtechLongevityMedical Devices
Jane Rhodes(Chief Executive Officer)inMagnus Ivarsson(Chief Scientific Officer)inHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in
.jpg)
Co-investorsBrandon CapitalDementia Discovery FundNovartis Venture FundSV Health InvestorsUCL Technology FundAlbionVC
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
Co-investorsLAVLilly Asia VenturesSchooner CapitalTaiho Ventures, LLC
BiotechGermantown, US
John Mumm(Executive Officer, Director)Vera Mumm(Executive Officer)Pavel Khrimian(Executive Officer, Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)
BoardLu Han(Director)in
Co-investorsATEM Capital FundLumira VenturesPlains VenturesEcho Investment CapitalLeaps by Bayer
ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.
BiotechDeep TechHealthtechWaltham, US
David Hallal(CEO)inMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in
Co-investorsEcoR1 CapitalSamsara BioCapitalSoftBank Vision Fund
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)inAlexandra Cantley(Director)inSeiji Miyahara(Director)in
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapital+4 more
Firefly Bio develops antibody-drug conjugates (ADCs) that use novel classes of payloads, drawing on a research team experienced in ADC discovery and development.
BiotechHealthtechMedical Devices
Scott Hirsch(CEO)inDan Kaplan(CSO)
Co-investorsDecheng Capital
Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.
Co-investorsLatterell Venture PartnersThe Vertical GroupOrbiMedVersant Ventures
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(CEO)inDan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsAgent CapitalDC Investment PartnersLifelinkLongwood FundM VenturesMedical Excellence Capital+5 more
K2 Therapeutics is a biotech company that identifies innovative drug assets and develops them into medicines using a hub-and-spoke model with cross-regional clinical trials.
BiotechHealthtech
Ying Huang, Ph.D.(Chief Executive Officer, Director)
Co-investorsAlpine Space VenturesAltimeter CapitalCapitalGICONIQKleiner PerkinsLightspeed Venture Partners+4 more
The page is an online gambling/betting operator ("OK9") targeting Vietnamese players, offering sports betting, online casino, slots, fish-shooting games, lottery, and card games.
Deep TechHardwareSpace TechWest Hollywood, US
Neeldev Kunjur(Executive Officer, Director)Karandev Kunjur(Executive Officer, Director)Karan Kunjur(Founder)inNeel Kunjur(Founder)in
Co-investorsAlpine Space VenturesAlso CapitalAsymmetric Capital PartnersCapitalGEarthrise VenturesFirst Round Capital+22 more
_imresizer.png)
Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.
AI & Machine LearningBiotechMedical Devices
Joe Bolen(Chief Executive Officer)Joe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)Ciaran Lawlor, Ph.D.(Chief Operating Officer)Frank Neumann, M.D., Ph.D.(Chief Medical Officer)Siva Sakhamuri(Chief Technology Officer)in
Co-investorsAstellas Venture Management LLCTaiho Ventures, LLC
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)Edward Hurwitz(Director)
Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersVida Ventures+1 more
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Co-investorsAju IB InvestmentEcoR1 CapitalEvolution VC PartnersOrbiMedOUP (Osage University Partners)Pfizer Venture Investments+6 more
BiotechOklahoma City, US
Scott Rollins, Ph.D.(Executive Officer, Director)David Falconer(Executive Officer)inRichard Alvarez(Executive Officer)inRussell Rother(Executive Officer)inRodger McEver, M.D.(Director)
BoardPhilip Jones, M.D.(Director)
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
BiotechCambridge, US
Robert Millman(Executive Officer, Director)
BoardTodd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)
Co-investorsARCH Venture PartnersF-Prime CapitalJDRF T1D FundORI CapitalSlater Technology Fund6 Dimensions Capital+4 more
SiO2 Materials Science develops precision molded polymer containers with thin glass-like barrier coatings for pharmaceutical and biopharmaceutical applications.
BiotechMedical DevicesNew MaterialsAuburn, US
Robert S. Abrams(Executive Officer, Director)inRobert Pangborn(Director)John Belfance(Director)Jean-Marie Painvin(Director)Thomas Strungmann(Director)Jared Morris(Director)
An Italian-language affiliate guide that reviews and ranks non-AAMS online casinos (foreign-licensed gambling sites) accessible to Italian players, comparing bonuses, game catalogs, payment methods, and licensing.
ConsumerGamingMedia & EntertainmentBridgewater, US
William Duke(Executive Officer)inKristine Peterson(Executive Officer, Director)
BoardDaniel Pelak(Director)Sean Traynor(Director)Ittai Harel(Director)inPaul Queally(Director)
Co-investorsAgate Medical Investments LPHLM Investment PartnersKaiser Permanente VenturesAbingworthPitangoWelsh, Carson, Anderson & Stowe
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Amphivena TherapeuticsBioInterveneBlade TherapeuticsFirefly Bio, Inc.HotKnot Therapeutics, Inc.Maverick TherapeuticsMoat BiotechnologyPotenza TherapeuticsRedona Therapeutics, Inc.Rekindle TherapeuticsTetherex Pharmaceuticals CorpTrieza TherapeuticsVesuvius PharmaceuticalsāshibioCoDa TherapeuticsIconic TherapeuticsIdun PharmaceuticalsiTeos TherapeuticsK2 TherapeuticsNeoVistaProtegoRadius HealthReNAgade TherapeuticsReunionTCR2
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 6
4 IPOs · 2 acquisitionsAktis OncologyNASDAQ: AKTSEntrada Therapeutics, Inc.NASDAQ: TRDADyne TherapeuticsNASDAQ: DYNSyndax PharmaceuticalsNASDAQ: SNDXForteBioacq. by PallSemma Therapeuticsacq. by Vertex Pharmaceuticals
Portfolio news
latest coverage across their companies
Syndax Pharmaceuticals · aol.com · Aug 12, 2026
K2 Space · finsmes.com · Jul 30, 2026
arGEN-X · umbrex.com · Jun 5, 2026
IPO stake values · per SEC filings · 3
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Aktis Oncology | 17.4% | $18.00 | Jan 2026 | $164.7M |
| Entrada Therapeutics, Inc. | 14.4% | $20.00 | Nov 2021 | $86.5M |
| Syndax Pharmaceuticals | 12.5% | $12.00 | Mar 2016 | $26M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has MPM BioImpact made?
- MPM BioImpact has 67 tracked investments, 6 of which have exited, including 8 dated in the last 24 months.
- What stage does MPM BioImpact invest at?
- MPM BioImpact invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is MPM BioImpact's typical check size?
- MPM BioImpact typically writes checks of $1M – $15M.
- What sectors does MPM BioImpact focus on?
- MPM BioImpact focuses on Biotech, Healthtech, Impact & Social Good, Longevity, Mental Health.
- Where is MPM BioImpact located?
- MPM BioImpact is headquartered in Boston, US.
- Does MPM BioImpact lead rounds?
- MPM BioImpact has led 5 of the 14 rounds where its role is on record.
- Who does MPM BioImpact co-invest with?
- MPM BioImpact most often shares deals with Vida Ventures, Astellas Venture Management LLC, Canaan Partners, among 64 tracked co-investors.
Co-investors · 39
Novartis Venture Fund is the corporate venture arm investing in life science companies, backing innovative drugs and treatments across various stages of growth.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university research and breakthrough science.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Deerfield Management Company is a healthcare-focused investment firm, founded in 1994, that advances healthcare through investment, intelligence, and philanthropy.
Abingworth is a transatlantic investment firm that has backed life science and healthcare companies since the early days of the biotechnology industry, investing in over 200 companies.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel, differentiated therapeutics and treatments addressing unmet patient needs, from preclinical through commercial stages.
MRL Ventures Fund (MRLV) is the therapeutics-focused corporate venture group of MSD (Merck & Co.), investing globally in early-stage, preclinical therapeutics companies and providing capital, board partnership and access to MSD's R&D domain expertise.
▶27 more co-investors
GV (Google Ventures)Kleiner PerkinsPolaris PartnersARCH Venture PartnersDigitalis VenturesVivo Capital6 Dimensions CapitalAndreessen Horowitz8VCAtlas VentureFrazier Healthcare PartnersQiming Venture PartnersMedical Excellence CapitalNovo HoldingsCatalio Capital Management, LPBessemer Venture PartnersNorwest Venture PartnersDraper Fisher Jurvetson (DFJ)Third Point VenturesEarlybird Venture CapitalSofinnova PartnersSR One Capital ManagementThe Column GroupTencent HoldingsCofounders CapitalPureos BioventuresJMI Equity
Firms observed investing alongside MPM BioImpact, from public investor directories. Shared companies are the overlap with MPM BioImpact's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Obvious is a venture capital firm focused on supporting founders building solutions to humanity's largest challenges across planetary health, human health, and economic health.
Social Discovery Ventures (SDV) is a global investment management company investing across venture capital, private equity, public markets, absolute return strategies, and real estate for over a decade.
Novo Holdings is the investment arm of the Novo Nordisk Foundation and a leading life science investor that also manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity assets.
Town Hall Ventures is a venture firm that invests in healthcare technology and services companies addressing critical patient needs, with a focus on underserved populations.